HCM
LAB icon

Highbridge Capital Management’s Standard BioTools LAB Stock Holding History

Highbridge Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-12,158
Closed -$298K – 1303
2014
Q3 		$298K Buy
+12,158
New +$342K ﹤0.01% 1003

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highbridge Capital Management's LAB Position: Q4 2014 in Review

Highbridge Capital Management sold out of Standard BioTools (LAB) in Q4 2014, closing a stake of 12,158 shares — an estimated $298K sold.

Highbridge Capital Management first reported a position in LAB in Q3 2014 and held it in 1 quarter. The position peaked at $298K in Q3 2014. 100 funds tracked by Wall St. Rank hold LAB as of Q4 2014.

  • Highbridge Capital Management reported no remaining Standard BioTools position as of Q4 2014 after selling out during the quarter.
  • Highbridge Capital Management sold 12,158 Standard BioTools shares in Q4 2014, an estimated $298K.
  • Highbridge Capital Management first reported a position in Standard BioTools in Q3 2014 and held it in 1 quarter.
  • Highbridge Capital Management's Standard BioTools position peaked at $298K in Q3 2014.
  • 100 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2014.

Based on Highbridge Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.